Well Referenced

Tag: ALA

n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity

This 2013 review outlines the neurobiological roles of n-3 polyunsaturated fatty acids (PUFAs), particularly docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and alpha-linolenic acid (ALA), in promoting adult neurogenesis and synaptic plasticity. These omega-3 fatty acids support brain function through antioxidant, anti-inflammatory, and anti-apoptotic actions. They enhance neurogenesis in the hippocampal

Read More »
June 26, 2025 No Comments

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

The study titled “Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies” (Antioxidants (Basel), 2020, PMID: 33086555) assessed the safety of α-lipoic acid (ALA) supplementation by analyzing data from 71 randomized placebo-controlled trials involving 4,749 participants (2,558 receiving ALA and 2,294 on placebo).

Read More »
June 26, 2025 No Comments

Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells

This in vitro study investigated the effects of alpha-lipoic acid (ALA) on thyroid cancer cell proliferation, migration, and invasion. Using four human thyroid cancer cell lines (BCPAP, HTH-83, CAL-62, and FTC-133), researchers found that ALA significantly suppressed cancer cell proliferation by activating the AMPK pathway, leading to the downregulation of

Read More »
June 26, 2025 No Comments

The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial

The study titled “The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial” (Diabetes Care, 2003, PMID: 12610036) is a randomized controlled trial investigating the effects of alpha-lipoic acid (ALA) on diabetic polyneuropathy. Involving 120 patients with type 2 diabetes and symptomatic polyneuropathy, participants received either

Read More »
June 26, 2025 No Comments

Alpha-Lipoic Acid and Diabetic Neuropathy

This review article explores the role of alpha-lipoic acid (ALA) in managing diabetic peripheral neuropathy, highlighting its antioxidant properties and therapeutic potential. ALA reduces oxidative stress, enhances reduced glutathione levels, and protects nerves from hyperglycemia-induced damage. Clinical trials have demonstrated that 600 mg of ALA daily, administered either intravenously or

Read More »
June 26, 2025 No Comments

Treatment of Symptomatic Diabetic Polyneuropathy With the Antioxidant Alpha-Lipoic Acid: A Meta-Analysis

The meta-analysis titled “Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis” (Diabet Med, 2004, PMID: 14984445) evaluated the efficacy and safety of intravenous alpha-lipoic acid (600 mg/day) over three weeks in diabetic patients with symptomatic polyneuropathy. Analyzing data from four randomized, double-masked, placebo-controlled trials (n=1,258), the

Read More »
June 26, 2025 No Comments

Alpha-lipoic acid as a new treatment option for Alzheimer’s disease–a 48 months follow-up analysis

This observational study examined the long-term effects of alpha-lipoic acid (ALA) supplementation in Alzheimer’s disease (AD) patients over 48 months. Participants received 600 mg of ALA daily, which appeared to slow cognitive decline compared to the typical progression of AD, as measured by the Mini-Mental State Examination (MMSE). ALA’s antioxidant

Read More »
June 26, 2025 No Comments

α-lipoic acid in patients with autosomal dominant polycystic kidney disease

The study titled “α-lipoic acid in patients with autosomal dominant polycystic kidney disease” (Nutrition, 2020, PMID: 31790890) investigated the effects of α-lipoic acid (ALA) supplementation on systemic inflammation, endothelial dysfunction, and atherosclerosis in patients with autosomal dominant polycystic kidney disease (ADPKD). In a six-month intervention, 33 patients received 1.6 g

Read More »
June 26, 2025 No Comments